| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.15M | 51.12M | 49.47M | 6.46M | 27.33M | 14.88M |
| Gross Profit | 0.00 | 47.92M | 49.47M | 6.46M | 27.33M | 14.88M |
| EBITDA | 27.94M | 51.28M | 50.67M | 4.71M | 28.39M | 16.26M |
| Net Income | 27.53M | 48.53M | 47.56M | 5.09M | 26.27M | 13.99M |
Balance Sheet | ||||||
| Total Assets | 390.96M | 366.75M | 320.46M | 159.26M | 156.27M | 117.26M |
| Cash, Cash Equivalents and Short-Term Investments | 8.08M | 19.89M | 22.26M | 31.74M | 15.81M | 12.64M |
| Total Debt | 3.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.13M | 1.31M | 523.00K | 517.00K | 418.00K | 122.00K |
| Stockholders Equity | 386.82M | 365.44M | 319.94M | 158.75M | 155.85M | 116.99M |
Cash Flow | ||||||
| Free Cash Flow | 3.61M | 1.79M | -1.28M | 3.98M | -539.00K | -1.97M |
| Operating Cash Flow | 3.61M | 1.79M | -1.28M | 3.98M | -539.00K | -1.97M |
| Investing Cash Flow | -13.07M | -1.13M | -121.83M | 14.15M | -8.89M | -88.38M |
| Financing Cash Flow | -2.35M | -3.03M | 113.63M | -2.20M | 12.60M | 103.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £3.92B | 12.35 | 6.50% | 7.21% | -7.11% | 0.45% | |
76 Outperform | £9.09B | 17.21 | 8.30% | 5.37% | 4.78% | -4.86% | |
75 Outperform | ― | 8.68 | 14.83% | 1.56% | -7.43% | -26.63% | |
73 Outperform | £958.29M | 9.78 | 7.11% | 2.70% | -4.38% | ― | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
64 Neutral | £166.37M | 13.59 | 9.72% | 21.31% | -15.65% | -12.27% | |
61 Neutral | $7.54B | -129.15 | -1.53% | 7.09% | 9.86% | -134.41% |
Nippon Active Value Fund (NAVF) announced its participation in the tender offer for Hogy Medical Co., Ltd., which will result in the company being taken private and delisted from the Tokyo Stock Exchange. NAVF, which holds an 8.58% stake in Hogy Medical, along with co-investors, will reinvest part of the proceeds from the transaction into a limited partnership formed by Carlyle, the acquiring entity’s sponsor. This move aligns with NAVF’s strategy to invest in undervalued companies and positions it to continue influencing Hogy Medical through its reinvestment approach, including the right to nominate a director in the new entity. The Transaction is expected to enhance shareholder value for NAVF while adhering to its mandate for capital growth.
Nippon Active Value Fund plc announced the release of its Monthly Factsheet as of November 30, 2025, which will soon be available on their website. This announcement highlights the company’s commitment to transparency and provides stakeholders with insights into its investment strategies and performance, potentially impacting investor confidence and market positioning.
Nippon Active Value Fund plc announced the availability of its Monthly Factsheet for October 2025, which can be accessed on its website. The fund’s focus on small-cap Japanese equities and its strategy of targeting undervalued companies could impact its market positioning and offer potential growth opportunities for shareholders.
Nippon Active Value Fund Plc announced that as of October 31, 2025, its issued share capital comprises 192,514,986 Ordinary Shares, each with a nominal value of £0.01, all carrying voting rights. This update is crucial for shareholders to determine their interest in the company, impacting their decision-making regarding shareholding notifications.
Nippon Active Value Fund Plc has issued 280,000 new ordinary shares at a price of 215.75 pence per share, which is above the net asset value per share. This issuance increases the company’s total ordinary shares with voting rights to 192,514,986, impacting shareholder calculations for legal and regulatory notifications regarding share capital interest.